DXR Stock Overview
A medical device company, provides blood volume measurement technology focused on blood volume testing. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Daxor Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.99 |
| 52 Week High | US$10.04 |
| 52 Week Low | US$7.11 |
| Beta | -0.54 |
| 11 Month Change | -1.53% |
| 3 Month Change | 6.14% |
| 1 Year Change | 13.80% |
| 33 Year Change | -16.99% |
| 5 Year Change | -5.02% |
| Change since IPO | 67.26% |
Recent News & Updates
Shareholder Returns
| DXR | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -2.6% | -0.7% | -2.1% |
| 1Y | 13.8% | 22.5% | 29.7% |
Return vs Industry: DXR underperformed the US Medical Equipment industry which returned 22.5% over the past year.
Return vs Market: DXR underperformed the US Market which returned 29.7% over the past year.
Price Volatility
| DXR volatility | |
|---|---|
| DXR Average Weekly Movement | 10.3% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DXR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: DXR's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | n/a | Michael Feldschuh | www.daxor.com |
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973.
Daxor Corporation Fundamentals Summary
| DXR fundamental statistics | |
|---|---|
| Market cap | US$43.11m |
| Earnings (TTM) | US$1.69m |
| Revenue (TTM) | US$154.21k |
25.8x
P/E Ratio282.2x
P/S RatioIs DXR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DXR income statement (TTM) | |
|---|---|
| Revenue | US$154.21k |
| Cost of Revenue | US$0 |
| Gross Profit | US$154.21k |
| Other Expenses | -US$1.53m |
| Earnings | US$1.69m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.35 |
| Gross Margin | 100.00% |
| Net Profit Margin | 1,094.00% |
| Debt/Equity Ratio | 5.1% |
How did DXR perform over the long term?
See historical performance and comparison